Search | Clinical Trials Finder

Conditions: Stroke
Interventions: Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR), Task Specific Training (TST); Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Neovascular (Wet) Age-related Macular Degeneration
Interventions: SKG0106; Genetic
Lead sponsor: Skyline Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Boston, Massachusetts • Katy, Texas • Norfolk, Virginia

Conditions: Psoriasis
Interventions: Observational (Non-Interventional) Registry; Other
Lead sponsor: CorEvitas; Network
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Adult Growth Hormone Deficiency
Interventions: Somapacitan; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 29
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Intestinal Health
Interventions: "Humanized" galacto-oligosaccharides (hGOS), Galacto-oligosaccharides (GOS), Matching Placebo; Dietary Supplement · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Primary Immune Deficiency Disorder
Interventions: Bivigam, Other; Biological
Lead sponsor: ADMA Biologics, Inc.; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 17
States / cities: Carpinteria, California • Walnut Creek, California • Centennial, Colorado + 12 more

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Female only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 20,167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2030
U.S. locations: 167
States / cities: Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 423 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Depressive Disorder, Major
Interventions: Standard of Care (SOC); Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock, Abdominal Compartment Syndrome
Interventions: Accuryn Monitoring System; Device
Lead sponsor: Potrero Medical; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Unresectable Stage III NSCLC
Interventions: Multiparametric Mobile Technology; Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Long Beach, California • Santa Ana, California • Englewood, Colorado + 15 more

Conditions: Deep Venous Thrombosis, Post-thrombotic Syndrome
Interventions: PET/CT; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Congenital Heart Disease, Aortic Valve Stenosis, Fetal Cardiac Disorder, Hypoplastic Left Heart Syndrome
Interventions: Fetal aortic balloon dilatation; Procedure
Lead sponsor: Queen Silvia Children's Hospital, Gothenburg, Sweden; Other
Eligibility: 23 Weeks to 31 Weeks
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: San Francisco, California • Columbus, Ohio

Conditions: Single-ventricle
Interventions: Spironolactone; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 6 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Head and Neck Cancer
Interventions: fluorine-18-labeled fluoro-misonidazole (18F-FMISO), 18F-FMISO PET scan, MRI, FDG PET/CT scan; Radiation · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2023
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more

Conditions: Prematurity; Extreme
Interventions: Near-infrared spectroscopy (NIRS) utilization; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 0 Hours to 24 Hours
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: HeartFlow, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Redwood City, California • Stanford, California • Durham, North Carolina

Conditions: Lymphedema, Breast Cancer
Interventions: Surgical Intervention, Conservative Complex Physical Decongestion Therapy; Procedure
Lead sponsor: University Hospital, Basel, Switzerland; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 4
States / cities: New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 1 more

Conditions: Lung Non-Small Cell Carcinoma, Melanoma
Interventions: Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Neuropathic Pain
Interventions: Surgical Management of Neuroma; Procedure
Lead sponsor: Axogen Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Tampa, Florida • Indianapolis, Indiana • Salt Lake City, Utah + 1 more

Conditions: Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
Interventions: Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT; Other · Drug
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older
Enrollment: 6,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 19 more

Conditions: Cancer-related Cognitive Dysfunction, Cytomegaloviral Infection, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Spinal Muscular Atrophy (SMA)
Interventions: Prospective observational registry, Zolgensma; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2038
U.S. locations: 50
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 45 more

Search by objective public record fields.

Cognitive Oriented Strategy Training Augmented Rehabilitation (COSTAR) Treatment Approach for Stroke

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

Safety, Tolerability, and Biosignature of Humanized Prebiotics in Healthy Adults

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

A Correlational Study: Breast Cancer-related Chest Wall Lymphedema, Quality of Life, and Shoulder Function

Psoriasis Longitudinal Assessment and Registry

Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

Collective Accuryn Physiologic Signals and Signatures

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.

Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT

Effect of Fetal Aortic Valvuloplasty on Outcomes

Fibrosis and the Fontan

Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients

Use of NIRS in Preterm Population Born at Altitude

The PLATFORM Study: Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts)

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

Pharmacokinetic Profiling of Pembrolizumab and Nivolumab in Patients With Melanoma and/or Non-Small Cell Lung Cancer

Surgical Treatment of Chronic Neuropathic Pain

Platform of Randomized Adaptive Clinical Trials in Critical Illness

Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)